期刊
STATISTICS IN MEDICINE
卷 24, 期 3, 页码 329-339出版社
WILEY
DOI: 10.1002/sim.1975
关键词
genomics; clinical trials; molecularly targeted therapeutics pharmacogenomics; sample size; normal mixture
The development of genomics-based technologies is demonstrating that many common diseases are heterogeneous collections of molecularly distinct entities. Molecularly targeted therapeutics is often effective only for some subsets patients with a conventionally defined disease. We consider the problem of design of phase III randomized clinical trials for the evaluation of a molecularly targeted treatment when there is an assay predictive of which patients will be more responsive to the experimental treatment than to the control regimen. We compare the conventional randomized clinical trial design to a design based on randomizing only patients predicted to preferentially benefit from the new treatment. Trial designs are compared based on the required number of randomized patients and the expected number of patients screened for randomization eligibility. Relative efficiency depends upon the distribution of treatment effect across patient subsets.. prevalence of the subset of patients who respond preferentially to the experimental treatment, and assay performance. Copyright (C) 2004 John Wiley Sons. Ltd.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据